Hümmert, Martin W.
Jendretzky, Konstantin F.
Fricke, Karin
Gingele, Marina
Ratuszny, Dominica
Möhn, Nora
Trebst, Corinna
Skripuletz, Thomas
Gingele, Stefan
Sühs, Kurt-Wolfram
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
Article History
Received: 10 February 2023
Accepted: 8 July 2023
First Online: 4 August 2023
Competing interests
: MWH received research support from Myelitis e. V. KFJ received research support from Else Kröner Fresenius Foundation and travel compensation and congress fee from Merck. KF reports no disclosures. MG reports no disclosures. DR reports no disclosures. NM received honoraria for scientific lectures from Merck and Biogen. CT received honoraria for consultation and expert testimony from Alexion Pharma Germany GmbH, Chugai Pharma Germany GmbH, and Roche Pharma GmbH. TS received research support from Alnylam Pharmaceuticals, Bristol-Myers Squibb Foundation for Immuno-Oncology, Claudia von Schilling Foundation, CSL Behring, Else Kröner Fresenius Foundation, Hannover Biomedical Research School (HBRS), Sanofi Genzyme, VHV Foundation and honoraria for lectures and travel grants from Alexion, Alnylam Pharmaceuticals, Bayer Vital, Biogen, Celgene, Centogene, CSL Behring, Euroimmun, Janssen, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens and Sobi. SG received research support from Alnylam Pharmaceuticals, CSL Behring, Else Kröner Fresenius Foundation, Deutsche Forschungsgemeinschaft and Hannover Biomedical Research School (HBRS), as well as consulting and/or lecture honoraria from Alnylam and Merck. KWS reports honoraria for lectures or travel reimbursements for attending meetings from Biogen, Merck and Bristol-Myers Squibb as well as research support from Bristol-Myers Squibb.